SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David C. Burns who wrote (3796)10/22/1999 10:37:00 AM
From: quidditch  Read Replies (2) of 10280
 
If the run rate doesn't begin to show meaningful improvement over the next 12 months, the available cash and equivalents is going to become an extremely sensitive number. With the loss this quarter at around $55 million, and with increased expense associated with significant new phase trials in 2000 and ramping marketing expense for xopenex and others to come, SEPR needs to begin to see an inflection point within the next year or so. Going to the capital markets for either debt or equity will be an expensive/very dilutive proposition, much more so than was the convertible, once liquidity begins to appear to be problemmatic.

Longer with a much higher position than I thought would ever be the case. But this stock is trying my soul. A far cry from early last Spring.

Yahoo club where the action is, as this thread withers. Cheers, all.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News